SAFETY AND IMMUNOGENICITY OF THE SYNTHETIC MALARIA VACCINE SPF66 IN A LARGE FIELD TRIAL
SAFETY AND IMMUNOGENICITY OF THE SYNTHETIC MALARIA VACCINE SPF66 IN A LARGE FIELD TRIAL
复制标题
DOI：
10.1093/infdis/166.1.139
复制
发表时间：
1992-07-01
影响因子：
6.4
通讯作者：
PATARROYO, ME
中科院分区：
文献类型：
--
作者：
AMADOR, R;MORENO, A;PATARROYO, ME
在对自然暴露于疟疾的大量人群中进行合成疟疾疫苗 SPf66 的首次现场试验中，居住在哥伦比亚太平洋沿岸的 9957 名 1 岁以上儿童接种了三剂疫苗。为了评估疫苗的安全性，每次免疫后30分钟和48小时进行临床观察。 95.7%的病例未出现不良反应。在4.3%的不良反应病例中，最常见的是局部硬结和红斑。在随机选择的一组疫苗接种者中，在第三次接种后测量了抗 SPf66 抗体滴度：93% 的疫苗接种者产生了 SPf66 抗体。其中，55%的滴度>1:1600。这些结果证明了 SPf66 疫苗在大型现场试验中的安全性和免疫原性。
In the first field trial with synthetic malaria vaccine SPf66 in a large population naturally exposed to malaria, 9957 persons >1 year old and residing on the Colombian Pacific coast received three doses of the vaccine. To evaluate vaccine safety, clinical observations were made 30 min and 48 h after each immunization. There were no adverse reactions in 95.7% of cases. In the 4.3% of cases with adverse reactions, local induration and erythema were the most frequent. In a randomly selected group of vaccinees, anti-SPf66 antibody titers were measured after the third dose: 93% of the vaccinees raised antibodies to SPf66. Among these, 55% had titers >1:1600. These results demonstrate the safety and immunogenicity of the SPf66 vaccine in a large field trial.